Printer Friendly

Mutations In Donors' Stem Cells May Cause Problems For Cancer Patients.

ST. LOUIS, Mo., January 15, 2020 -- A Washington University School of Medicine study suggests that extremely rare, harmful genetic mutations present in healthy donors' stem cells--though not causing health problems in the donors --may be passed on to cancer patients receiving stem cell transplants, potentially creating health problems for the recipients.

Among the concerns are heart damage, graft-versus-host disease and possible new leukemias.

A stem cell transplant --also called a bone marrow transplant--is a common treatment for blood cancers, such as acute myeloid leukemia (AML).

Such treatment can cure blood cancers but also can lead to life-threatening complications, including heart problems and graft-versus-host disease, in which new immune cells from the donor attack a patient's healthy tissues.

The intense chemo- and radiation therapy prior to transplant and the immunosuppression given after allow cells with these rare mutations the opportunity to quickly replicate, potentially creating health problems for the patients who receive them, according to the research.

The study, involving samples from patients with AML and their stem cell donors, suggests such rare, harmful mutations are present in surprisingly young donors and can cause problems for recipients even if the mutations are so rare as to be undetectable in the donor by typical genome sequencing techniques.

The research opens the door to a larger study that will investigate these rare mutations in many more healthy donors, potentially leading to ways to prevent or mitigate the health effects of such genetic errors in patients receiving stem cell transplants.

"There have been suspicions that genetic errors in donor stem cells may be causing problems in cancer patients, but until now we didn't have a way to identify them because they are so rare," said senior author Todd E. Druley. "This study raises concerns that even young, healthy donors' blood stem cells may have harmful mutations and provides strong evidence that we need to explore the potential effects of these mutations further."

Transplant physicians tend to seek younger donors because it is assumed this will lead to fewer complications.

But now there is evidence that even young and healthy donors can have mutations that will have consequences for patients.

Those consequences need to be understood to find ways to modify them.

The study analyzed bone marrow from 25 adult patients with AML whose samples had been stored in a repository at Washington University.

Samples from their healthy matched donors, who were unrelated to the patients, also were sequenced.

The donors' samples were provided by the Center for International Blood and Marrow Transplant Research in Milwaukee.

The 25 AML patients were chosen because they each had had samples banked at four separate times: before the transplant, at 30 days post-transplant, at 100 days, and at one year.

Druley co-invented a technique called error-corrected sequencing to identify extremely rare DNA mutations that would be missed by conventional genome sequencing.

Typical next-generation sequencing techniques can correctly identify a mutation that is present in one in 100 cells.

The new method, which can distinguish between true mutations and mistakes introduced by the sequencing machine, allows the researchers to find true mutations that are extremely rare: those present in as few as one in 10,000 cells.

The healthy donors ranged in age from 20 to 58, with an average age of 26.

The researchers sequenced 80 genes known to be associated with AML, and they identified at least one harmful genetic mutation in 11 of the 25 donors, or 44 percent.

They further showed that 84 percent of all the various mutations identified in the donors' samples were potentially harmful, and that 100 percent of the harmful mutations present in the donors later were found in the recipients.

These harmful mutations also persisted over time, and many increased in frequency. Such data suggest the harmful mutations from the donor confer a survival advantage to the cells that harbor them.

"We didn't expect this many young, healthy donors to have these types of mutations," Druley said. "We also didn't expect 100 percent of the harmful mutations to be engrafted into the recipients. That was striking."

According to the researchers, the study raises questions about the origins of some of the well-known side effects of stem cell transplantation.

"We see a trend between mutations from the donor that persist over time and the development of chronic graft-versus-host disease," said first author Wing Hing Wong, a doctoral student in Druley's lab. "We plan to examine this more closely in a larger study."

Though the study was not large enough to establish a causal link, the researchers found that 75 percent of the patients who received at least one harmful mutation in the 80 genes that persisted over time developed chronic graft-versus-host disease.

Among patients who did not receive mutations in the 80 genes, about 50 percent developed the condition.

Because the study was small, this difference was not statistically significant, but it is evidence that the association should be studied more closely. In general, about half of all patients who receive a stem cell transplant go on to develop some form of graft-versus-host disease.

The most common mutation seen in the donors and the cancer patients studied is in a gene associated with heart disease.

Healthy people with mutations in this gene are at higher risk of heart attack due to plaque buildup in the arteries.

"We know that cardiac dysfunction is a major complication after a bone marrow transplant, but it's always been attributed to toxicity from radiation or chemotherapy," Druley said. "It's never been linked to mutations in the blood-forming cells. We can't make this claim definitively, but we have data to suggest we should study that in much more detail."

Now that these mutations were linked to graft-versus-host disease and cardiovascular problems, a larger study is planned that could answer some of the questions posed by this study.

Citation: Wing Hing Wong et al., Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. Science Translational Medicine, 2020; 12 (526): eaax6249 DOI: 10.1126/scitranslmed.aax6249


Contact: Todd E. Druley,
COPYRIGHT 2020 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Stem Cells & Cancer
Publication:Stem Cell Research News
Date:Jan 27, 2020
Previous Article:Trial Tests Stem Cell Transplantation Versus Best Available Therapy For MS.
Next Article:Cancer Study Finds That One Gene Pushes Stems Cells To Make Blood Stem Cells.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters